One-year investigator-blind randomized multicenter trial comparing asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis

Inflammatory Bowel Diseases

Volumn 18, Issue 10, 2012, Pages 1885-1893

  Hawthorne, A Barney ^a   Stenson, Rachel ^a   Gillespie, David ^b   Swarbrick, Edwin T ^c   Dhar, Anjan ^d   Kapur, Kapil C ^e   Hood, Kerry ^b   Probert, Chris S J ^f  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c NEW CROSS HOSPITAL   (United Kingdom)

^d BISHOP AUCKLAND GENERAL HOSPITAL   (United Kingdom)

^e BARNSLEY DISTRICT GENERAL HOSPITAL   (United Kingdom)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

adherence; clinical trial; mesalazine; ulcerative colitis

Indexed keywords

CREATININE; MESALAZINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; REMISSION; SIDE EFFECT; SINGLE BLIND PROCEDURE; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MESALAMINE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; RESEARCH PERSONNEL; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 84866366042     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21938     Document Type: Article

References (35)

1. Sutherland L, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database System Rev. 2002; CD000544.
2. D'Inca R, Bertomoro P, Mazzocco K, et al. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2008; 27: 166-172. (Pubitemid 350256604)
3. Shale MJ, Riley SA,. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18: 191-198. (Pubitemid 36951655)
4. Hussain FN, Ajjan RA, Kapur K, et al. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther. 2001; 15: 53-62. (Pubitemid 32055586)
5. Rao SS, Read NW, Brown C, et al. Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology. 1987; 93: 934-940. (Pubitemid 18000634)
6. Rao SS, Read NW,. Gastrointestinal motility in patients with ulcerative colitis. Scand J Gastroenterol Suppl. 1990; 172: 22-28. (Pubitemid 20206662)
7. Sandborn WJ, Hanauer SB,. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003; 17: 29-42. (Pubitemid 36140432)
8. Kane S, Huo D, Magnanti K,. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003; 1: 170-173. (Pubitemid 37248066)
9. Baron JH, Connell AM, Lennard-Jones JE,. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964; 1: 89-92.
10. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007; 132: 66-75. (Pubitemid 46108735)
11. Schroeder KW, Tremaine WJ, Ilstrup DM,. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317: 1625-1629. (Pubitemid 18010466)
12. Ardizzone S, Petrillo M, Molteni P, et al. Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. J Clin Gastroenterol. 1995; 21: 287-289.
13. Courtney MG, Nunes DP, Bergin CF, et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet. 1992; 339: 1279-1281.
14. Giaffer MH, Holdsworth CD, Lennard-Jones JE, et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther. 1992; 6: 479-485.
15. Green JR, Gibson JA, Kerr GD, et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3g daily and mesalazine 1.2g daily over 12;months. Aliment Pharmacol Ther. 1998; 12: 1207-1216. (Pubitemid 28565960)
16. Green JRB, Swan CHJ, Rowlinson A, et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther. 1992; 6: 647-652.
17. Kiilerich S, Ladefoged K, Rannem T, et al. Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group. Gut. 1992; 33: 252-255.
18. Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci. 1995; 40: 296-304.
19. Mulder CJ, Tytgat GN, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology. 1988; 95: 1449-1453. (Pubitemid 19016199)
20. Paoluzi OA, Iacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 vs. 1.2g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther. 2005; 21: 1111-1119. (Pubitemid 40646537)
21. Rijk MCM, Lier HJJ, Tongeren JHM,. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. Am J Gastroenterol. 1992; 87: 438-442.
22. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut. 1988; 29: 669-674.
23. Rutgeerts P,. Comparative efficacy of coated, oral 5-aminosalicyclic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1989; 3.
24. Wright JP, O'Keefe EA, Cuming L, et al. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig Dis Sci. 1993; 38: 1837-1842. (Pubitemid 23311935)
25. Ardizzone S, Petrillo M, Imbesi, et al. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther. 1999; 13: 373-379. (Pubitemid 29142047)
26. Statistical Package for the Social Sciences, Version 16.0. Chicago: SPSS; 2009.
27. Kane SV,. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006; 23: 577-585.
28. Sandborn WJ, Korzenik J, Lashner B, et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010; 138: 1286-1296, 1296 e1-3.
29. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005; 54: 364-368. (Pubitemid 40299092)
30. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119: 15-22. (Pubitemid 30452574)
31. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990; 150: 1881-1884. (Pubitemid 20316533)
32. Horne R, Weinman J,. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health. 2002; 17: 17-32.
33. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008; 57: 893-902. (Pubitemid 351919522)
34. Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009; 7: 762-769.
35. Kruis W, Jonaitis L, Pokrotnieks J, et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011; 33: 313-322.